name: Hemochromatosis
creation_date: '2026-01-09T07:07:01Z'
updated_date: '2026-02-16T20:19:38Z'
category: Mendelian
disease_term:
  preferred_term: hereditary hemochromatosis
  term:
    id: MONDO:0006507
    label: hereditary hemochromatosis
parents:
- Iron Metabolism Disorders
- Hereditary Metabolic Diseases
pathophysiology:
- name: HFE Loss Lowers Hepcidin
  description: >
    Pathogenic HFE variants (most commonly C282Y homozygosity) blunt hepcidin induction,
    leaving circulating hepcidin inappropriately low relative to body iron stores.
  evidence:
  - reference: PMID:23985001
    supports: SUPPORT
    snippet: "Hereditary hemochromatosis is an inherited iron overload disorder caused by inappropriately low hepcidin secretion leading to increased duodenal absorption of dietary iron, most commonly in C282Y homozygous individuals."
    explanation: Impaired HFE signaling results in low hepcidin in C282Y homozygotes.
  biological_processes:
  - preferred_term: regulation of iron ion transport
    term:
      id: GO:0034756
      label: regulation of iron ion transport
  - preferred_term: negative regulation of iron ion transport
    term:
      id: GO:0034757
      label: negative regulation of iron ion transport
  downstream:
  - target: Low Hepcidin Leads to Ferroportin Hyperabsorption
    description: Inappropriately low hepcidin releases the ferroportin brake on intestinal iron efflux.

- name: Low Hepcidin Leads to Ferroportin Hyperabsorption
  description: >
    Suppressed hepcidin fails to internalize and degrade ferroportin on enterocytes, so
    dietary iron efflux into plasma is unchecked, driving systemic iron overload.
  evidence:
  - reference: PMID:23985001
    supports: PARTIAL
    snippet: "Hereditary hemochromatosis is an inherited iron overload disorder caused by inappropriately low hepcidin secretion leading to increased duodenal absorption of dietary iron"
    explanation: Low hepcidin permits unregulated ferroportin-mediated iron export from the gut.
  biological_processes:
  - preferred_term: positive regulation of intestinal absorption
    term:
      id: GO:1904480
      label: positive regulation of intestinal absorption
  - preferred_term: iron ion export across plasma membrane
    term:
      id: GO:1903988
      label: iron ion export across plasma membrane
  - preferred_term: positive regulation of iron ion transport
    term:
      id: GO:0034758
      label: positive regulation of iron ion transport
  cell_types:
  - preferred_term: enterocyte
    term:
      id: CL:0000584
      label: enterocyte
  downstream:
  - target: Hepatic Iron Toxicity
    description: Increased gut iron transfer elevates circulating iron and drives hepatic deposition.
  - target: Cardiac Iron Deposition
    description: Chronic plasma iron loading promotes myocardial iron accumulation.
  - target: Pancreatic Iron Toxicity
    description: Systemic iron excess leads to iron deposition in pancreatic islets.
- name: Hepatic Iron Toxicity
  description: >
    Excess iron deposits in hepatocytes leading to oxidative stress, lipid peroxidation,
    and hepatocellular damage. Progressive iron accumulation causes fibrosis and can
    lead to cirrhosis and hepatocellular carcinoma.
  evidence:
  - reference: PMID:37763705
    supports: PARTIAL
    snippet: "The key organ that is affected by iron overload is the liver, suffering from fibrosis, cirrhosis or hepatocellular carcinoma"
    explanation: Liver iron overload drives fibrotic injury and malignant risk.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: cellular response to oxidative stress
    term:
      id: GO:0034599
      label: cellular response to oxidative stress
  - preferred_term: intrinsic apoptotic signaling pathway in response to oxidative stress
    term:
      id: GO:0008631
      label: intrinsic apoptotic signaling pathway in response to oxidative stress
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  downstream:
  - target: Hepatomegaly
    description: Hepatocyte injury and remodeling contribute to progressive liver enlargement.
- name: Cardiac Iron Deposition
  description: >
    Iron accumulation in cardiomyocytes causes oxidative damage and impaired contractility,
    leading to cardiomyopathy and cardiac failure, particularly dilated cardiomyopathy.
  evidence:
  - reference: PMID:35449524
    supports: PARTIAL
    snippet: "Hemochromatosis type 2 or juvenile hemochromatosis has an early onset of severe iron overload resulting in organ manifestation such as liver fibrosis, cirrhosis, cardiomyopathy, arthropathy, hypogonadism, diabetes"
    explanation: Early severe iron overload includes cardiomyopathy, consistent with cardiac iron toxicity.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: cellular response to oxidative stress
    term:
      id: GO:0034599
      label: cellular response to oxidative stress
  - preferred_term: regulation of heart contraction
    term:
      id: GO:0008016
      label: regulation of heart contraction
  - preferred_term: response to iron ion
    term:
      id: GO:0010039
      label: response to iron ion
  downstream:
  - target: Cardiomyopathy
    description: Oxidative myocardial injury and contractile dysfunction manifest as cardiomyopathy.
- name: Pancreatic Iron Toxicity
  description: >
    Iron deposition in pancreatic beta cells causes oxidative damage and impaired insulin
    secretion, leading to diabetes mellitus ("bronze diabetes").
  evidence:
  - reference: PMID:38886778
    supports: PARTIAL
    snippet: "Magnetic resonance imaging showed iron deposition in the liver, spleen, and pancreas, along with cirrhosis and splenomegaly."
    explanation: Imaging confirms pancreatic iron deposition contributing to endocrine dysfunction.
  cell_types:
  - preferred_term: type B pancreatic cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: cellular response to oxidative stress
    term:
      id: GO:0034599
      label: cellular response to oxidative stress
  - preferred_term: negative regulation of insulin secretion
    term:
      id: GO:0046676
      label: negative regulation of insulin secretion
  - preferred_term: response to iron(II) ion
    term:
      id: GO:0010040
      label: response to iron(II) ion
  downstream:
  - target: Diabetes Mellitus
    description: Beta-cell dysfunction from iron toxicity impairs insulin output and drives diabetes.
phenotypes:
- name: Hepatomegaly
  description: >
    Enlarged liver due to iron accumulation in hepatocytes, often the earliest
    detectable physical finding.
  phenotype_term:
    preferred_term: hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: PMID:37168645
    supports: PARTIAL
    snippet: "One of the most serious clinical characteristics associated with early-onset iron overload is liver disease with eventual cirrhosis"
    explanation: Liver involvement early in disease course leads to enlargement and progression to cirrhosis.
- name: Skin Hyperpigmentation
  description: >
    Bronze or grayish skin discoloration due to increased melanin and iron deposition
    in the dermis, a classic feature of hemochromatosis.
  phenotype_term:
    preferred_term: generalized bronze hyperpigmentation
    term:
      id: HP:0007574
      label: Generalized bronze hyperpigmentation
  evidence:
  - reference: PMID:38886778
    supports: PARTIAL
    snippet: "The proband is a 64-year-old man complaining of persistent abnormality of liver enzyme levels for 1 year, with a history of knee joint pain, diabetes and skin pigmentation."
    explanation: Case report documents skin pigmentation in ferroportin-related hemochromatosis.
- name: Diabetes Mellitus
  description: >
    Development of diabetes due to pancreatic beta cell destruction from iron toxicity,
    historically called "bronze diabetes."
  phenotype_term:
    preferred_term: diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  evidence:
  - reference: PMID:38886778
    supports: PARTIAL
    snippet: "The proband is a 64-year-old man complaining of persistent abnormality of liver enzyme levels for 1 year, with a history of knee joint pain, diabetes and skin pigmentation."
    explanation: Diabetes reported as part of the hemochromatosis presentation.
- name: Arthropathy
  description: >
    Joint pain and swelling, particularly affecting the second and third
    metacarpophalangeal joints, due to iron and calcium pyrophosphate deposition.
  phenotype_term:
    preferred_term: arthropathy
    term:
      id: HP:0003040
      label: Arthropathy
  evidence:
  - reference: PMID:38886778
    supports: PARTIAL
    snippet: "The proband is a 64-year-old man complaining of persistent abnormality of liver enzyme levels for 1 year, with a history of knee joint pain, diabetes and skin pigmentation."
    explanation: Knee joint pain in hemochromatosis supports arthropathy association.
- name: Cardiomyopathy
  description: >
    Heart muscle disease due to iron deposition in cardiomyocytes, which can lead
    to heart failure and arrhythmias.
  phenotype_term:
    preferred_term: cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
  evidence:
  - reference: PMID:35449524
    supports: PARTIAL
    snippet: "Hemochromatosis type 2 or juvenile hemochromatosis has an early onset of severe iron overload resulting in organ manifestation such as liver fibrosis, cirrhosis, cardiomyopathy, arthropathy, hypogonadism, diabetes"
    explanation: Juvenile hemochromatosis case describes cardiomyopathy among manifestations.
- name: Hypogonadism
  description: >
    Decreased gonadal function due to iron deposition in the pituitary gland,
    leading to reduced libido, erectile dysfunction, and testicular atrophy.
  phenotype_term:
    preferred_term: hypogonadotropic hypogonadism
    term:
      id: HP:0000044
      label: Hypogonadotropic hypogonadism
  evidence:
  - reference: PMID:36644615
    supports: PARTIAL
    snippet: "Pituitary haemochromatosis is an endocrine disorder caused by the accumulation of iron due to a lack of absorption during haemochromatosis."
    explanation: Pituitary iron deposition disrupts gonadotropin signaling leading to hypogonadism.
- name: Fatigue
  description: >
    Chronic tiredness and weakness, one of the most common and earliest symptoms
    of hemochromatosis.
  phenotype_term:
    preferred_term: fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:39337031
    supports: SUPPORT
    snippet: "The HH patients exhibited significantly worse fatigue across all the scales."
    explanation: Fatigue questionnaires show higher fatigue burden in HH compared with controls.
  - reference: PMID:30244162
    supports: SUPPORT
    snippet: "It results in chronic fatigue and in potential liver (cirrhosis), pancreas (diabetes) and joint (arthritis) damage in adulthood."
    explanation: Long-term cohort notes chronic fatigue as a characteristic manifestation of genetic hemochromatosis.
treatments:
- name: Phlebotomy (Therapeutic Venesection)
  description: >
    Regular blood removal is the primary treatment, which reduces iron stores by
    requiring the body to use iron for new red blood cell production. Initially
    weekly until iron stores normalize, then maintenance every 2-3 months.
  evidence:
  - reference: PMID:23985001
    supports: SUPPORT
    snippet: "Phlebotomy remains the mainstay of treatment and new treatments being studied include erythrocytapheresis and 'mini-hepcidins'."
    explanation: "This review confirms phlebotomy as the standard first-line treatment for hereditary hemochromatosis."
  - reference: PMID:38886778
    supports: SUPPORT
    snippet: "Four patients with organ damage in the present study received therapeutic phlebotomy, alleviating clinical symptoms and improving in transferrin saturation and serum ferritin."
    explanation: Phlebotomy improved iron indices and symptoms in a ferroportin hemochromatosis pedigree.
  - reference: PMID:37121243
    supports: SUPPORT
    snippet: "Early diagnosis by genetic testing and therapy by periodic phlebotomy can prevent the most serious complications, which include liver cirrhosis, liver cancer, and death."
    explanation: Seminar notes phlebotomy prevents cirrhosis and mortality when started early.
  - reference: PMID:35662478
    supports: SUPPORT
    snippet: "Early diagnosis and treatment by phlebotomy can prevent cirrhosis, hepatocellular carcinoma, diabetes, arthropathy and other complications."
    explanation: EASL guideline highlights phlebotomy as preventive for multi-organ complications.
  - reference: PMID:5339192
    supports: PARTIAL
    snippet: "The treatment of hemochromatosis by phlebotomy."
    explanation: Early clinical report established phlebotomy as definitive iron removal.
- name: Iron Chelation Therapy
  description: >
    Deferoxamine or oral chelators (deferasirox, deferiprone) are used when
    phlebotomy is contraindicated or insufficient, such as in patients with anemia.
  evidence:
  - reference: PMID:19727383
    supports: PARTIAL
    snippet: "Because secondary hemochromatosis is due to hereditary or acquired anemia, phlebotomy is not a suitable means of removing excess iron in this situation. Rather, the treatment is based on the targeted elimination of iron by means of iron chelators."
    explanation: Secondary hemochromatosis requires chelation when phlebotomy is not feasible.
  - reference: PMID:29620054
    supports: SUPPORT
    snippet: "The mainstay therapy is phlebotomy, although iron chelation can be used in some patients."
    explanation: Primer notes chelation as an alternative for selected patients.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Dietary Modification
  description: >
    Avoiding iron supplements, limiting vitamin C intake (which enhances iron
    absorption), and reducing alcohol consumption to protect the liver.
  evidence:
  - reference: PMID:38361672
    supports: PARTIAL
    snippet: "This patient was counseled on lifestyle modifications which included abstaining from alcohol and reducing iron and vitamin C intake. As a result, his iron panel parameters improved."
    explanation: Lifestyle changes in alcohol and dietary iron/Vitamin C improved iron indices.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
- name: Screening of Family Members
  description: >
    Genetic testing of first-degree relatives is recommended given the autosomal
    recessive inheritance pattern and the benefits of early intervention.
  evidence:
  - reference: PMID:37121243
    supports: PARTIAL
    snippet: "Early diagnosis by genetic testing and therapy by periodic phlebotomy can prevent the most serious complications, which include liver cirrhosis, liver cancer, and death."
    explanation: Emphasizes early genetic testing to enable preventive treatment.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
differential_diagnoses:
- name: Secondary/Transfusional Iron Overload
  description: >
    Iron accumulation from chronic transfusions or ineffective erythropoiesis can mimic hereditary hemochromatosis but occurs in anemic patients where phlebotomy is not feasible.
  distinguishing_features:
  - History of chronic transfusions or underlying anemia (e.g., thalassemia, MDS)
  - Phlebotomy contraindicated due to anemia; chelation preferred
  - Iron loading often involves reticuloendothelial system in addition to parenchyma
  evidence:
  - reference: PMID:19727383
    supports: SUPPORT
    snippet: "Because secondary hemochromatosis is due to hereditary or acquired anemia, phlebotomy is not a suitable means of removing excess iron in this situation. Rather, the treatment is based on the targeted elimination of iron by means of iron chelators."
    explanation: Highlights anemia/transfusion-related iron overload where chelation is required instead of phlebotomy.
- name: Ferroportin Disease (SLC40A1-Related Hemochromatosis)
  description: >
    Autosomal dominant iron overload from gain-of-function SLC40A1 variants can present with high ferritin and iron deposition, necessitating distinction from HFE-hemochromatosis.
  distinguishing_features:
  - Often autosomal dominant inheritance pattern
  - Elevated ferritin with variable transferrin saturation; iron may accumulate in macrophages and liver
  - Genetic testing reveals SLC40A1 variants affecting ferroportin
  evidence:
  - reference: PMID:38886778
    supports: SUPPORT
    snippet: "SLC40A1-related haemochromatosis is associated with gain-of-function mutations in the SLC40A1 gene, which encodes ferroportin."
    explanation: Establishes ferroportin-associated iron overload as a distinct entity to differentiate.
genetic:
- name: HFE Mutations
  association: Causative
  notes: Most common mutation is C282Y (p.Cys282Tyr) homozygosity, accounting for 80-90% of hereditary hemochromatosis cases. H63D (p.His63Asp) compound heterozygosity also contributes.
  inheritance:
  - name: Autosomal Recessive
  evidence:
  - reference: PMID:23985001
    supports: SUPPORT
    snippet: "most commonly in C282Y homozygous individuals"
    explanation: "Review confirms C282Y homozygosity as the most common cause of hereditary hemochromatosis."
datasets:
